Muhammad Ansari, MD
Interventional Cardiology · Hannibal, MONPI 1225103765
Payments from drug & device makers
Across 357 payments — averaging $31.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Medtronic$2K
- Angiodynamics, Inc.$1K
- Bard Peripheral Vascular, Inc.$786
- Abbott$758
- Johnson & Johnson$735
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$1,50013%
- Travel & lodging$2,91826%
- Food & beverage$6,90161%
- Education$410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 35 | $2,250 |
| Medtronic(2 entities) | 27 | $1,936 |
| Angiodynamics, Inc. | 8 | $1,421 |
| Bard Peripheral Vascular, Inc. | 4 | $786 |
| Abbott | 26 | $758 |
| Johnson & Johnson | 70 | $735 |
| Amgen | 33 | $591 |
| Novartis | 28 | $409 |
| Pfizer | 17 | $276 |
| E.r. Squibb & Sons, L.L.C. | 14 | $233 |
| Edwards Lifesciences | 4 | $211 |
| Shockwave Medical, Inc | 17 | $189 |
| Abiomed | 3 | $187 |
| Boston Scientific | 6 | $145 |
| AstraZeneca | 10 | $143 |
| Boehringer Ingelheim | 6 | $102 |
| Chiesi USA, Inc. | 5 | $96 |
| Innova Vascular Inc. | 1 | $92 |
| Teleflex LLC | 1 | $89 |
| Biotronik Inc. | 5 | $80 |
| Vifor Pharma, Inc. | 4 | $79 |
| Merck | 5 | $77 |
| Gilead | 4 | $58 |
| Cvrx, Inc. | 3 | $53 |
| Cardiovascular Systems Inc. | 6 | $45 |
| Inari Medical, Inc. | 1 | $39 |
| Terumo Medical Corporation | 1 | $37 |
| Amarin Pharma, Inc. | 2 | $34 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Imperative Care, Inc | 1 | $24 |
| Covidien LP | 1 | $24 |
| ERMI LLC | 1 | $23 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$1,689
- Auryon Laser System 100-120 Vac$1,379
- Crosser iQ$767
- SYMPLICITY G3$751
- Micra$474
- ESPRIT$202
- CoreValve Evolut$170
- SAPIEN 3 Ultra RESILIA$152
How this compares
$11,360 in reported general payments places this provider in the 45th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $119,787 |
| JardianceEmpagliflozin | 38 | $35,313 |
| XareltoRivaroxaban | 36 | $27,708 |
| FarxigaDapagliflozin Propanediol | 13 | $13,329 |
| EntrestoSacubitril/Valsartan | 14 | $11,522 |
| Praluent PenAlirocumab | 11 | $5,308 |
| Ranolazine ErRanolazine | 34 | $2,277 |
| Bisoprolol Fumarate | 69 | $1,300 |
| Ezetimibe | 52 | $1,229 |
| Nebivolol Hcl | 25 | $1,127 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 86 | $961 |
| Metoprolol Succinate | 66 | $867 |
| ClopidogrelClopidogrel Bisulfate | 80 | $831 |
| Amlodipine Besylate | 144 | $828 |
| Atorvastatin Calcium | 75 | $736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $276 | $119,787140 claims |
| Boehringer IngelheimJardiance | $102 | $35,31338 claims |
| Johnson & JohnsonXarelto | $735 | $27,70836 claims |
| AstraZenecaFarxiga | $143 | $13,32913 claims |
| NovartisEntresto | $409 | $11,52214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Hannibal
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
- Jasvindar SinghSaint Louis$993K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.